Equities

Hbm Holdings Ltd

Hbm Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.24
  • Today's Change0.01 / 0.81%
  • Shares traded706.00k
  • 1 Year change-18.42%
  • Beta2.0878
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

HBM Holdings Ltd is an investment holding company mainly engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.

  • Revenue in HKD (TTM)562.82m
  • Net income in HKD166.02m
  • Incorporated2016
  • Employees158.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tianda Pharmaceuticals Ltd384.68m-47.26m509.56m695.00--0.9358--1.32-0.022-0.0220.17890.25330.43412.974.46445,745.10-5.34---7.97--45.83---12.30--0.6748-9.510.1536--------------
3D Medicines Inc539.11m-495.99m557.73m198.00--0.5964--1.03-2.11-2.112.263.620.37464.945.792,722,764.00-37.27---50.88--91.97---99.50--2.56--0.2517--11.91--48.78------
Lee's Pharmaceutical Holdings Ltd1.20bn63.06m694.83m1.06k11.020.40553.540.57950.10710.10712.042.910.44032.119.701,134,410.001.9813.332.5217.7651.4961.924.5036.200.74256.120.1323.59-14.61-1.53-67.44-47.49-12.19-31.34
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd925.32m189.30m733.93m678.003.880.41995.780.79320.33790.33791.653.120.35742.102.941,091,177.007.317.6710.2510.4875.4678.7920.4620.681.62--0.05027.22-0.00495.38-23.43-1.67-1.14--
Zhaoke Ophthalmology Ltd63.10m-250.42m748.21m297.00--0.3337--11.86-0.4597-0.45970.11584.110.02331.250.8868201,601.40-9.23---10.51--82.03---396.86--5.48-24.020.1114------5.47------
Fusen Pharmaceutical Co Ltd469.27m-98.90m749.96m1.14k--1.31--1.60-0.1326-0.13260.62990.76540.32121.683.35408,769.60-6.770.9678-13.961.7453.1851.95-21.082.590.526-2.270.403127.9515.024.13-4.83--0.2124--
Jbm (Healthcare) Ltd648.42m130.46m756.24m279.006.220.78794.121.170.14790.14790.73381.170.46454.255.982,324,068.009.834.3812.045.5252.1446.4721.1612.691.2589.680.115532.9824.6216.09128.5119.992.26--
Pak Fah Yeow International Ltd265.21m96.45m804.03m101.008.341.077.753.030.30940.30940.85072.410.28692.8423.532,600,118.0010.443.9911.324.1887.0580.7936.3721.274.225.260.0055100.6876.0612.94250.6623.0218.83-8.06
Zhongzhi Pharmaceutical Holdings Ltd2.25bn122.77m820.42m2.74k6.550.67223.900.3640.1450.1452.661.411.092.686.10852,889.205.997.699.1711.7557.5560.445.496.730.903343.870.151642.4612.2612.4153.0013.8617.653.22
Hbm Holdings Ltd562.82m166.02m952.48m158.005.500.95124.851.690.22570.22570.76341.300.32583.9616.673,179,801.009.59-54.6113.25-66.0495.5797.8129.42-400.283.448.140.3502--120.13127.06116.61---12.62--
Ascletis Pharma Inc11.13m-285.07m997.39m219.00--0.4212--89.63-0.2746-0.27460.01072.370.00411.343.5850,813.03-10.47-6.43-10.85-6.64-125.1735.67-2,561.69-243.3824.31-4.180.004--4.63-19.3954.04---20.44--
Jacobson Pharma Corporation Ltd1.47bn210.24m1.18bn1.72k5.390.49253.350.8040.10950.13910.76441.200.33112.476.37851,885.104.744.305.765.5742.2741.2514.3213.731.735.330.238240.6215.79-0.14011.31-3.0524.064.10
Essex Bio-Technology Ltd1.62bn262.89m1.28bn1.46k5.020.63644.040.79230.44990.44992.733.550.55872.622.731,093,064.009.0711.2012.1014.7389.7886.0116.2419.771.61--0.139716.1629.517.7222.113.567.297.39
SinoMab Bioscience Ltd2.23m-220.18m1.34bn215.00--4.40--600.98-0.2114-0.21140.00210.27980.0023----10,392.71-22.83-24.62-29.11-27.7226.80---9,853.75-4,451.74----0.6339------14.45--106.81--
VIVA Biotech Holdings2.20bn-350.72k1.36bn2.04k--0.32295.300.6184-0.0056-0.00561.071.950.26035.265.141,059,453.000.4017-1.390.5601-1.6833.6634.811.54-5.441.462.630.2884---9.4259.3178.03--31.98--
Data as of Sep 20 2024. Currency figures normalised to Hbm Holdings Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.84%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 05 Sep 20245.21m0.68%
SSgA Funds Management, Inc.as of 05 Sep 20241.18m0.15%
Dimensional Fund Advisors Ltd.as of 30 Jun 202442.04k0.01%
DFA Australia Ltd.as of 31 Jul 202413.10k0.00%
China Universal Asset Management Co., Ltd.as of 31 Dec 20230.000.00%
China Asset Management (Hong Kong) Ltd.as of 30 Jun 20240.000.00%
Bosera Asset Management Co., Ltd.as of 31 Dec 20230.000.00%
More ▼
Data from 30 Jun 2024 - 12 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.